Igm Biosciences Stock Investor Sentiment

IGMS Stock  USD 1.36  0.02  1.49%   
Slightly above 71% of IGM Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding IGM Biosciences suggests that many traders are alarmed. IGM Biosciences' investing sentiment can be driven by a variety of factors including economic data, IGM Biosciences' earnings reports, geopolitical events, and overall market trends.
  

IGM Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards IGM Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at www.macroaxis.com         
Acquisition by Takimoto Chris H of 43750 shares of IGM Biosciences subject to Rule 16b-3
Macroaxis News
2 days ago at news.google.com         
IGM Biosciences, Inc. Expected to Beat Earnings Estimates What to Know Ahead of Q4 Release - Yahoo F...
Google News at Macroaxis
over two weeks ago at simplywall.st         
Were Keeping An Eye On IGM Biosciences Cash Burn Rate
Simply Wall St News at Macroaxis
over three weeks ago at kalkinemedia.com         
IGM Biosciences Develops Promising Therapies Amid Financial Challenges
news
over three weeks ago at zacks.com         
Down -76.91 percent in 4 Weeks, Heres Why IGM Biosciences Looks Ripe for a Turnaround
zacks News
over three weeks ago at finance.yahoo.com         
Down -76.91 percent in 4 Weeks, Heres Why IGM Biosciences Looks Ripe for a Turnaround
Yahoo News
over a month ago at news.google.com         
IGM Biosciences stock plunges to 52-week low of 1.59 - MSN
Google News at Macroaxis
over a month ago at news.google.com         
Igm biosciences principal accounting officer sells 1,907 in stock - Investing.com
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 1122 shares by Steven Weber of IGM Biosciences at 1.6999 subject to Rule 16b-3
Macroaxis News
over a month ago at news.google.com         
JP Morgan Upgrades IGM Biosciences - MSN
Google News at Macroaxis
over a month ago at news.google.com         
JPMorgan Chase Co. Upgrades IGM Biosciences to Neutral - MarketBeat
Google News at Macroaxis
over a month ago at gurufocus.com         
IGM Biosciences Shares Drop 68 percent as Company Halts Key Programs and Cuts Workforce
Gurufocus Stories at Macroaxis
over a month ago at bizjournals.com         
Drug company job cuts surged last year, and this year is starting with more
bizjournals News
over a month ago at www.macroaxis.com         
Acquisition by Baker Bros. Advisors Lp of 1994 shares of IGM Biosciences subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Schwarzer Fred of 3000 shares of IGM Biosciences at 5.02 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about IGM Biosciences that are available to investors today. That information is available publicly through IGM media outlets and privately through word of mouth or via IGM internal channels. However, regardless of the origin, that massive amount of IGM data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of IGM Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of IGM Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to IGM Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive IGM Biosciences alpha.

IGM Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 1708 shares by Misbah Tahir of IGM Biosciences at 7.48 subject to Rule 16b-3
12/16/2024
2
IGM Biosciences NASDAQIGMS shareholders incur further losses as stock declines 21 percent this week, taking five-year losses to 84
12/18/2024
3
Acquisition by Strohl William of 125000 shares of IGM Biosciences subject to Rule 16b-3
12/27/2024
4
Acquisition by Redmile Group, Llc of 1734 shares of IGM Biosciences subject to Rule 16b-3
12/31/2024
5
Acquisition by Baker Bros. Advisors Lp of 1994 shares of IGM Biosciences subject to Rule 16b-3
01/03/2025
6
JP Morgan Upgrades IGM Biosciences - MSN
01/14/2025
7
Disposition of 1122 shares by Steven Weber of IGM Biosciences at 1.6999 subject to Rule 16b-3
01/15/2025
8
IGM Biosciences stock plunges to 52-week low of 1.59 - MSN
01/28/2025
9
IGM Biosciences Develops Promising Therapies Amid Financial Challenges
02/06/2025
10
Acquisition by Takimoto Chris H of 43750 shares of IGM Biosciences subject to Rule 16b-3
02/28/2025

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.